Polynovo to test biopolymer 'glue' for new bionic ear
22 October, 2004 by Graeme O'NeillPolyNovo Biomaterials, a 50-per cent owned subsidiary of Perth's Xceed Biotechnology (ASX:XBL), has entered a research alliance with Melbourne's Bionic Ear Institute to develop a more sophisticated bionic ear that could dramatically improve patients' hearing by inducing new auditory nerves to grow and connect with the bionic implant.
Vioxx pushes Merck profit down; analyst predicts takeover
22 October, 2004 by Staff WritersNew Jersey-based Merck has reported a 28 per cent drop in quarterly profit and said 2004 earnings will fall as much as 11 per cent due to last month's recall of its Vioxx arthritis drug.
Visiomed awaits FDA clearance for Funhaler
22 October, 2004 by Melissa TrudingerVisiomed (ASX: VSG) is readying itself to commence marketing and distribution of its Funhaler device worldwide, although it is still awaiting US FDA clearance for the product.
Amrad scores third $3m milestone payment
22 October, 2004 by Melissa TrudingerAmrad (ASX: AML) will receive its third US$3 million payment from Merck & Co after reaching another preclinical milestone in the development of new asthma therapies based on the IL-13 receptor.
Moses says Amrad undervalued; receives $3m from Merck
21 October, 2004 by Melissa TrudingerAmrad (ASX: AML) chairman Bob Moses told shareholders at the company's AGM that the company remained significantly undervalued, even though it had successfully restructured and refocused its portfolio to concentrate on inflammation and cancer, and spinning out the anti-infectives projects into Avexa.
Genzyme posts third quarter profit
21 October, 2004 by Staff WritersGenzyme has posted a third-quarter profit compared to a loss last year, when it took a big charge associated with an acquisition.
Alchemia soars: looks to break down the walls of antibiotic resistance
21 October, 2004 by Graeme O'NeillShares in Brisbane drug-developer Alchemia (ASX:ACL) rose 50 per cent to $0.80 today, on the back of news that it would be targeting antibiotic-resistant "superbugs" with a novel class of synthetic molecules that disrupt cell-wall synthesis in bacteria.
Mice appear to thrive without junk DNA
21 October, 2004 by Staff WritersMice -- and perhaps humans -- can thrive when large amounts of so-called junk DNA are deleted from their genome, according to results of experiments reported in the October 21 issue of Nature.
Benitec grants Panomics ddRNAi licence, eyes reagents market
20 October, 2004 by Graeme O'NeillBrisbane biotech Benitec (ASX:BLT) shares were up 8 per cent to $0.65 today after it announced it had granted a worldwide, non-exclusive licence to Panomics, of Redwood City in California. The licence allows Panomics to make and sell products that exploit Benitec's patented DNA-directed RNAi gene-silencing technology.
Proteome Systems in cancer diagnostic collaboration
20 October, 2004 by Melissa TrudingerNewly-listed Proteome Systems (ASX: PXL) has entered into a collaboration with researchers at the Westmead Children's Hospital and Westmead Millennium Institute to develop diagnostics for the early diagnosis and monitoring of ovarian cancer.
Regenera receives ethics approval for second clinical trial
20 October, 2004 by Renate KrellePerth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.
Cryptome CEO resigns
19 October, 2004 by Melissa TrudingerCryptome Pharmaceuticals (ASX: CRP) has announced that CEO Jeffrey Travis has resigned for personal reasons.
Rockeby says test can also apply to children
19 October, 2004 by Renate KrelleRockeby's (ASX:RBY) laboratory-based SysCan tests for Candida antibody levels is likely to be useful for diagnosing the infection in children, a trial in Singapore has found.
Prana heading for the clinic
19 October, 2004 by Graeme O'NeillMelbourne brain-drug developer Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) will move its is lead Alzheimer's disease drug PBT-1 (clioquinol) into a Phase II/III clinical trial in the first half of next year, with the aim of carving up to three years from the time required to deliver the drug to the clinic.
Eqitx vaccine research results published
18 October, 2004 by Graeme O'NeillA research paper in the prestigious US journal Proceedings of the National Academy of Science this week has underscored the commercial potential of the platform vaccine technology being commercialised by Eqitx (ASX:EQX) subsidiary VacTX, the company has claimed.
